It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain’s regulation of body temperature,” the FDA said in a statement announcing the drug’s approval. “This is the first-of-its-kind medication, a neurokinin 3 (NK3) receptor antagonist, that tackles moderate to severe hot flashes where they begin - the brain,” she said.įezolinetant, which goes by the brand name Veozah, “targets the neural activity which causes hot flashes during menopause. Progestagen-only contraceptives carry similar, small breast cancer risk as other hormone contraceptives, study finds The most exciting addition to the guidelines - so new it had to be inserted just before publication - is a nonhormonal medication recently approved by the FDA called fezolinetant, which is available by prescription, Shufelt said.īirth control pills on pink background, close up. Not only do the vast majority of women experience hot flashes, for a third of women they can last more than 10 years, Shufelt said. “We’re not talking about depression, sleep or anxiety symptoms in these guidelines.” “Specifically, what we’re talking about are hot flashes and the accompanying night sweats because those are the most common,” Faubion said. For the 2023 update, experts evaluated the latest studies on nonhormone medical, herbal and behavioral therapy and lifestyle approaches for vasomotor symptoms - the medical term for hot flashes. That guidance, published Monday in the journal Menopause, updates an older 2015 position statement. For all of these women, we want to provide evidence-based guidance on alternate methods to help manage their hot flashes,” said Shufelt, chair of an advisory council that produced the “2023 Nonhormone Therapy Position Statement” of the North American Menopause Society. “And some women have a personal preference not to take HRT. Chrisandra Shufelt, professor and associate director of the Women’s Health Research Center at Mayo Clinic in Jacksonville, Florida. “However, some women are not good candidates for hormone therapy because of contraindications, such as a personal or strong family history of estrogen-dependent cancers, cardiovascular disease, stroke, blood clotting disorders, deep venous thrombosis and chronic liver disease,” said Dr. Hormone replacement therapy, also called HRT, is still the preferred choice of treatment for menopausal symptoms - which can include hot flashes, chills, night sweats, sleep problems, mood changes, vaginal dryness and pain during sex. Stephanie Faubion, director of the Mayo Clinic’s Center for Women’s Health in Jacksonville, Florida, and medical director for the North American Menopause Society. Hot flashes - and the night sweats they produce - will plague some 80% of people transitioning to menopause, defined as the lack of a menstrual period for 12 consecutive months, said Dr. Alzheimer’s and HRT: Study suggests sweet spot to avoid dementia
0 Comments
Leave a Reply. |